ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 444. Bittencourt HS, Reis HF, Lima MS, Gomes M Neto. Non-Invasive Ventilation in patients with heart failure: a systematic review and meta- analysis. Arq Bras Cardiol. 2017;108(2):161-8. 445. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al; SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375(10):919-31. 446. Abuzaid AS, Al Ashry HS, Elbadawi A, Ld H, Saad M, Elgendy IY, et al. Meta-analysis of cardiovascular outcomes with continuous positive airway pressure therapy in patients with obstructive sleep apnea. Am J Cardiol. 2017;120(4):693-9. 447. Lenneman CG, Kimmick GG, Sawyer DB. Epidemiology of cardio- oncology. In: Kimmick GG, LenihanDJ, Sawyer DB, Mayer EL, Hershman DL. Cardio-oncology: the clinical overlap of cancer and heart disease. Switzerland: Springer; 2017. p. 1-14. 448. Ewer MS, von Hoff DD, Benjamin RS. A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin. 2011;7(3):363-72. 449. Banke A, Schou M, Videbæk L, Møller JE, Torp-Pedersen C, Gustafsson F, et al. Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. Eur J Heart Fail. 2016;18(3):260-6. 450. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ET. Cardiovascular complications of cancer therapy. J AmColl Cardiol. 2017;70(20):2536-51. Erratum in: J Am Coll Cardiol. 2018;71(5):587. 451. Darby SC, EwertzM, McGale P, Bennet AM, Blom-GoldmanU, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast câncer. N Engl J Med. 2013;368(11):987-98. 452. Cosper PF, Leinwand LA. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. 2011;71(5):1710-20. 453. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, FagerlandMW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671-80. 454. Avila MS, Ayub-Ferreira SM, de Barros Wanderley Junior MR, Cruz FdD, Gonçalves Brandão SM, Carvalho Rigaud VO, et al. Carvedilol for prevention of chemotherapy related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71(20):2281-90. 455. Zamorano JL, Lancellotti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESCPosition Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19(1):9-42. 456. Walker J, Bhullar N, Fallah-Rad N, LytwynM, GolianM, Fang T, et al. Role of three-dimensional echocardiography in breast cancer: comparisonwith two-dimensional echocardiography, multiple-gated acquisition scans, and cardiacmagnetic resonance imaging. J ClinOncol. 2010;28(21):3429-36. 457. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic ressonance imaging. J Clin Oncol. 2012;30(23):2876-84. 458. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77-84. 459. NegishiK,NegishiT,HareJL,HaluskaBA,PlanaJC,MarwickTH.Independent and incrementalvalueofdeformation indicesforpredictionoftrastuzumab- induced cardiotoxicity. J AmSoc Echocardiogr. 2013;26(5):493-8. 460. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-39. 461. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;35(8):893-911. 462. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-8. 463. Kalil Filho R, Hajjar LA, Bacal F, Hoff PM, Diz Mdel P, Galas FR, et al; Grupo de Estudos em Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (GEIC/SBC); Sociedade Brasileira de Oncologia Clínica; Instituto do Coração – Faculdade de Medicina da Universidade de São Paulo; Instituto do Câncer do Estado de São Paulo – Faculdade de Medicina da Universidade de São Paulo. [I BrazilianGuideline for Cardio- Oncology from Sociedade Brasileira de Cardiologia]. Arq Bras Cardiol. 2011;96(2 Suppl 1):1-52. 464. RutledgeT,ReisVA,LinkeSE,GreenbergBH,MillsPJ.Depressioninheartfailure ameta-analyticreviewofprevalence,interventioneffects,andassociationswith clinicaloutcomes.JAmCollCardiol.2006;17;48(8):1527-37. 465. Gathright EC, Goldstein CM, Josephson RA, Hughes JW. Depression increases the risk of mortality in patients with heart failure: ameta-analysis. J Psychosom Res. 2017 Mar;94:82-9. 466. Newhouse A, Jiang W. Heart failure and depression. Heart Fail Clin. 2014;10(2):295-304. 467. Tu RH, Zeng ZY, Zhong GQ, WuWF, Lu YJ, Bo ZD, et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Eur J Heart Fail. 2014;16(7):749-57. 468. Freedland KE, Carney RM, RichMW, Steinmeyer BC, Rubin EH. Cognitive behavior therapy for depression and self-care in heart failure patients: a randomized clinical trial. JAMA Intern Med. 2015;175(11):1773-82. 469. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART- CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692-9. 470. Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R, et al; MOOD-HF Study Investigators and Committee Members. Effect of escitalopram on all –cause mortality and hospitalization in patients with heart failure and depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315(24):2683-93. 471. Rajeswaran T, Plymen CM, Doherty AM. The effect of antidepressant medications in the management of heart failure on outcomes: mortality, cardiovascular function and depression – a systematic review.Int J Psychiatry Clin Pract. 2018;22(3):164-9. 472. Gonçalves JG, Dias Silva VJ, Calzada Borges MC, Prata A, Correia D. Mortality indicators among chronic Chagas patients living in an endemic area. Int J Cardiol. 2010;143(3):235-42. 473. Bestetti RB, Daniel RA. The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era. International Cardiovascular Forum Journal. 2016;7:19-25. 474. Bezerra CG, Adam EL, Baptista ML, Ciambelli GS, Kopel L, Bernoche C, et al. Aortic counterpulsation therapy in patients with advanced heart failure: analysis of the TBRIDGE registry. Arq Bras Cardiol. 2016;106(1):26-32. 475. Petti MA, Viotti R, Armenti A, Bertocchi G, Lococco B, Alvarez MG, et al. [Predictors of heart failure in chronic chagasic cardiomyopathy with asymptomatic left ventricular dysfunction]. Rev Esp Cardiol. 2008;61(2):1116-22. 530